Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115228) titled 'A multicenter, double-blind, placebo-parallel-controlled Phase ? clinical trial to evaluate the safety, efficacy and pharmacokinetic characteristics of KR230109 in patients with acne vulgaris' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking University People's Hospital
Condition:
Acne vulgaris
Intervention:
Experimental group 1:KR230109 0.025%Group
Experimental group 2:KR230109 0.05%Group
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2025-12-26
Target Sample Size: Experimental group 1:60;Experimental group 2:60;placebo group:6...